Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The firm engages in the development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Collegium Pharmaceutical reports record Q1 revenue amidst patent challenges

Collegium Pharmaceutical's Q1 2023 performance showcased record revenue and strong financial management strategies.
The company faces challenges from patent infringement risks and generic competition, requiring a focus on defending IP and market positioning.
Opportunities in volume growth, business development, and strategic investments in key products position Collegium for long-term success.
Maintaining a balance between defending IP, managing expenses, and driving growth will be crucial for Collegium's future performance.

Collegium Pharmaceutical posts record revenue and growth, eyes strategic acquisitions

Collegium Pharmaceutical reported strong financial performance in Q2 2023, with a focus on achieving a banner year. Despite challenges with Xtampza ER and growth expectations, the company remains committed to improving access, reducing debt, and returning capital to shareholders.

Collegium Pharmaceutical excels in Q3, eyes growth opportunities ahead

Collegium Pharmaceutical reports strong Q3 2023 performance with record revenue and EBITDA growth, driven by successful contract renegotiations and operational efficiency.
Challenges include mitigating declining scripts, navigating patient profiles, and sustaining growth amidst market uncertainties, requiring strategic adjustments and foresight.
Opportunities lie in Medicare Part D market expansion, differentiated asset focus, and strategic valuations, positioning Collegium for future growth and market leadership.

Collegium Pharmaceutical reports record revenue and strategic wins in pain management market

Collegium Pharmaceutical's Q4 2023 earnings call highlighted exceptional financial achievements, robust product performance, and strategic wins in the pain management market. While facing challenges in maintaining guidance and addressing analyst queries, the company remains optimistic about its future outlook and growth potential.

Collegium Pharmaceutical reports strong Q1 earnings amidst leadership transition

Collegium Pharmaceutical's Q1 2024 earnings call highlighted strong financial performance, leadership transition, and growth strategies.
Despite challenges such as CEO resignation and competitive landscape dynamics, the company remains focused on its market position and growth potential.
Opportunities for business development priorities and strategic partnerships offer avenues for future growth and expansion.

Collegium Pharmaceutical reports record Q3 performance and navigates market challenges

Collegium Pharmaceutical's Q3 performance showcased robust financial results and strategic moves to strengthen their market position. While facing challenges in formulary changes and market competition, the company is well-positioned to leverage opportunities in the ADHD market and drive continued growth.

Collegium Pharmaceuticals excels in Q4 2024, poised for strategic growth

Collegium Pharmaceuticals delivered robust financial results in Q4 2024, showcasing revenue growth, record EBITDA, and strategic investments in shareholder value. The company's focus on Journee and pain portfolio optimization, along with leadership enhancements, positions it well for sustained growth and market competitiveness. While facing challenges in capital deployment and cost management, Collegium can capitalize on opportunities for expansion, partnerships, and financial optimization. Overall, Collegium's performance highlights a balanced approach to growth, financial discipline, and strategic planning for long-term success in the pharmaceutical industry.

Collegium Pharmaceutical excels in Q1 2025, reaffirms strong guidance

Collegium Pharmaceutical's Q1 2025 earnings call highlighted strong financial performance, strategic priorities, and reaffirmed guidance, showcasing a commitment to growth and shareholder value. The company's focus on responsible pain management, diversification, and operational excellence positions it well for future success. While facing challenges in a competitive market, Collegium's opportunities lie in driving growth, maximizing portfolio potential, and prudent capital deployment.

Collegium Pharmaceutical reports robust Q2 earnings and growth opportunities

Collegium Pharmaceutical's Q2 2025 earnings call showcased strong financial performance, driven by revenue growth and strategic investments. The company's focus on Jornay PM and the pain portfolio, along with raised financial guidance, indicates a positive outlook for future growth. While challenges in sustaining momentum and managing growth exist, Collegium's strengths in strategic priorities and commitment to patients position it well for success. Exploring opportunities for market expansion and innovation could further enhance Collegium's growth trajectory and competitive position.

Collegium Pharmaceuticals excels in Q3, eyes growth and innovation

Collegium Pharmaceuticals' Q3 2025 performance reflects strong revenue growth, strategic focus on key products, and prudent financial management. While facing competitive challenges, the company's commitment to innovation, market expansion, and shareholder value creation positions it for continued success. Opportunities for growth through product optimization, market expansion, and strategic partnerships underscore Collegium's potential for long-term value creation.

Collegium Pharmaceutical reports record earnings, poised for strategic growth

Collegium Pharmaceutical's Q4 2025 earnings call showcased exceptional performance, marked by record revenues and EBITDA, driven by Jornay PM and pain portfolio success. While facing questions on growth assumptions and competition, Collegium's strong financials and strategic focus position it well for continued success and value creation. With a focus on driving growth, maximizing portfolio potential, and disciplined capital deployment, Collegium aims to sustain its momentum and create shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.